Pfizer to provide 6 million Paxlovid therapies to International Fund

Pfizer will provide as much as six million Paxlovid therapies to the International Fund in an effort towards equitable entry to COVID-19 oral therapies, the corporate introduced Thursday.

The massive image: Some 132 nations can have entry to the antiviral tablet based mostly on “revenue classification and illness burden” by means of the International Fund, which connects governments, well being organizations and the personal sector to assist low-income nations deal with and forestall illness.

Particulars: Pfizer says it expects provide to be accessible someday this yr based mostly on nation wants and allocations decided by International Fund.

  • Eligible nations might be supplied remedy programs in keeping with Pfizer’s tiered pricing strategy, by which all low- and lower-middle-income nations pays a not-for-profit worth, the corporate stated.
  • Higher-middle-income nations pays a worth outlined within the tiered pricing strategy. Particulars of the settlement weren’t disclosed.

What they’re saying: “After a lot disruption and loss as a consequence of COVID-19, we should proceed to speed up entry to PAXLOVID as a secure and efficient remedy choice for high-risk sufferers in all areas of the world together with take a look at and deal with packages that assist get remedy shortly to these in want,” Pfizer CEO Albert Bourla stated in a press release.

Sure however: Whereas Paxlovid has been efficient at maintaining older, sicker folks out of the hospital with COVID, questions linger about its effectiveness in youthful age teams and the rebound noticed in some sufferers who take it, Axios’ Arielle Dreher stories.

State of play: The CDC recommends Paxlovid for these over the age of fifty, and for these with medical circumstances like lung or coronary heart illness.

  • The drug’s emergency authorization, nevertheless, covers anybody 12 or older.
See also  Excessive insulin costs lead some adults to ration

Go deeper: “Sport-changer” Paxlovid turns into pandemic enigma